Lancet:新的血液检测可预测患肺结核的危险性

2016-03-25 崔倩 译 MedSci原创

世界人口的三分之一被认为感染了结核分枝杆菌(结核杆菌),该细菌会导致结核病(TB),但只是一小部分人群曾经出现症状性疾病。现在,一个国际研究小组已潜伏感染的人群中确定了生物标志物,这可能成为医生的工具,也是他们一直在寻求的血液生物标志物:一种方法来预测谁是发生活动性结核病的高危人群。如果通过更多的临床试验证实,基于这些血液生物标志物的测试将允许医生靶向治疗有风险的人群,从而防止该人群发病。这十年的

世界人口的三分之一被认为感染了结核分枝杆菌(结核杆菌),该细菌会导致结核病(TB),但只是一小部分人群曾经出现症状性疾病。现在,一个国际研究小组在已潜伏感染的人群中确定了生物标志物,这可能成为医生的工具,也是他们一直在寻求的血液生物标志物:一种方法来预测发生活动性结核病的高危人群。如果通过更多的临床试验证实,基于这些血液生物标志物的测试将允许医生靶向治疗有风险的人群,从而防止该人群发病。

这十年的研究工作是由来自开普顿大学南非结核疫苗倡议小组的研究人员,西雅图传染病研究中心研究所领导的。它是在由美国国立卫生研究院提供部分资金资助的。

生物标记在两个阶段中进行鉴定。首先,研究人员在南非在两年内收集了来自6000多名结核杆菌感染但原本健康的青少年志愿者的血液样本。样品的分析结果表明,基因表达模式在TB志愿者和那些仍保持健康的青少年之间是不同的。这种风险“标志”仅限于一组16个基因,可在患TB人群在感染前18个月时在血液样品中被检测到。

接下来,研究小组证实了在南非和冈比亚超过4500名志愿者中进行证实遗传风险标志的预测能力。在这项研究中志愿者均健康,但住在一起,并且最近被诊断出患有活动性结核病。第二个研究小组中年龄、健康状况、种族和接触结核杆菌的情况比第一项研究中的志愿者更加多样化。尽管存在差异,在第二项试验期间,在最终患活动性结核病人群中检测到与第一项研究中相同的风险标志。

原始出处:

Daniel E Zak, Adam Penn-Nicholson, Thomas J Scriba,A blood RNA signature for tuberculosis disease risk: a prospective cohort study,Lancet,2016.3.23

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1828441, encodeId=49341828441f7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 16:46:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253981, encodeId=da53125398154, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363612, encodeId=6910136361265, content=<a href='/topic/show?id=40708928907' target=_blank style='color:#2F92EE;'>#血液检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89289, encryptionId=40708928907, topicName=血液检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73815, encodeId=b794e3815f4, content=希望是这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73816, encodeId=05a7e3816d7, content=现在结核还是难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73785, encodeId=188ae378513, content=值得期待,希望有所突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Mar 25 20:08:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73764, encodeId=fcf9e37641b, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Fri Mar 25 19:20:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
    2016-07-19 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1828441, encodeId=49341828441f7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 16:46:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253981, encodeId=da53125398154, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363612, encodeId=6910136361265, content=<a href='/topic/show?id=40708928907' target=_blank style='color:#2F92EE;'>#血液检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89289, encryptionId=40708928907, topicName=血液检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73815, encodeId=b794e3815f4, content=希望是这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73816, encodeId=05a7e3816d7, content=现在结核还是难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73785, encodeId=188ae378513, content=值得期待,希望有所突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Mar 25 20:08:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73764, encodeId=fcf9e37641b, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Fri Mar 25 19:20:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1828441, encodeId=49341828441f7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 16:46:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253981, encodeId=da53125398154, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363612, encodeId=6910136361265, content=<a href='/topic/show?id=40708928907' target=_blank style='color:#2F92EE;'>#血液检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89289, encryptionId=40708928907, topicName=血液检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73815, encodeId=b794e3815f4, content=希望是这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73816, encodeId=05a7e3816d7, content=现在结核还是难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73785, encodeId=188ae378513, content=值得期待,希望有所突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Mar 25 20:08:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73764, encodeId=fcf9e37641b, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Fri Mar 25 19:20:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1828441, encodeId=49341828441f7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 16:46:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253981, encodeId=da53125398154, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363612, encodeId=6910136361265, content=<a href='/topic/show?id=40708928907' target=_blank style='color:#2F92EE;'>#血液检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89289, encryptionId=40708928907, topicName=血液检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73815, encodeId=b794e3815f4, content=希望是这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73816, encodeId=05a7e3816d7, content=现在结核还是难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73785, encodeId=188ae378513, content=值得期待,希望有所突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Mar 25 20:08:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73764, encodeId=fcf9e37641b, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Fri Mar 25 19:20:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
    2016-03-26 milkshark

    希望是这样

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1828441, encodeId=49341828441f7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 16:46:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253981, encodeId=da53125398154, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363612, encodeId=6910136361265, content=<a href='/topic/show?id=40708928907' target=_blank style='color:#2F92EE;'>#血液检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89289, encryptionId=40708928907, topicName=血液检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73815, encodeId=b794e3815f4, content=希望是这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73816, encodeId=05a7e3816d7, content=现在结核还是难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73785, encodeId=188ae378513, content=值得期待,希望有所突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Mar 25 20:08:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73764, encodeId=fcf9e37641b, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Fri Mar 25 19:20:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
    2016-03-26 milkshark

    现在结核还是难题

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1828441, encodeId=49341828441f7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 16:46:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253981, encodeId=da53125398154, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363612, encodeId=6910136361265, content=<a href='/topic/show?id=40708928907' target=_blank style='color:#2F92EE;'>#血液检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89289, encryptionId=40708928907, topicName=血液检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73815, encodeId=b794e3815f4, content=希望是这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73816, encodeId=05a7e3816d7, content=现在结核还是难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73785, encodeId=188ae378513, content=值得期待,希望有所突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Mar 25 20:08:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73764, encodeId=fcf9e37641b, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Fri Mar 25 19:20:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
    2016-03-25 dhzzm

    值得期待,希望有所突破

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1828441, encodeId=49341828441f7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 16:46:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253981, encodeId=da53125398154, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363612, encodeId=6910136361265, content=<a href='/topic/show?id=40708928907' target=_blank style='color:#2F92EE;'>#血液检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89289, encryptionId=40708928907, topicName=血液检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun Mar 27 05:46:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73815, encodeId=b794e3815f4, content=希望是这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73816, encodeId=05a7e3816d7, content=现在结核还是难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:43:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73785, encodeId=188ae378513, content=值得期待,希望有所突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Mar 25 20:08:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73764, encodeId=fcf9e37641b, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Fri Mar 25 19:20:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
    2016-03-25 1de304d2m86(暂无匿称)

    好好学习

    0

相关资讯

Science:一滴血检测病毒感染史

霍华德休斯医学研究所(HHMI)的研究人员开发了一项新的技术,使人们有可能通过一滴血来检测目前和曾经任何已知人类病毒的感染情况。这个方法称为VirScan,是一种有效的测试病毒感染的替代诊断方法。文章发表在最新一期的Science杂志上。VirScan工作原理是筛查血液中存在的针对任何206种已知感染人类的病毒的抗体。我们的免疫系统在检测到病毒首次入侵的时候,会产生病原体特异性抗体,即使病毒感染清

Alzheimer''s & Dementia:老年痴呆可血液检测?

近日研究发现,简单的血液测试可用来检测老年人早期阿尔茨海默病。在血液检测前需要详细的标准化指导指南来指导实践,相关文章已发表在《阿尔茨海默病和痴呆》杂志上。“如果我们使阿尔茨海默氏症的血液测试成为初级保健的必检项目,那么我们必须有指导指南。”Sid O ' bryant博士说,他是北德克萨斯大学保健中心衰老和阿尔茨海默氏症研究所研究中心主任。“高度严格的指导指南将指导研究阿尔茨海默氏症以血液为基础

STM:血液检测可预测乳腺癌药物抵抗

  科学家最近开发出一种具有高灵敏度的血液检测方法,可以确定乳腺癌何时对标准激素治疗法产生抵抗,他们还证明这种检测方法能够指导病人如何进行进一步治疗。   研究人员表示这种方法能够在乳腺癌细胞对芳香酶抑制剂产生抵抗的早期阶段给予病人警告,芳香酶抑制剂是治疗雌激素受体阳性乳腺癌的常用药物。他们发现这种新方法能够检测雌激素受体基因ESR1发生的基因突变,特别是接受了芳

Cell:新型血检技术或可扩大液体活检的范围

当细胞死亡后,其并不会消失地无影无踪,相反其会以游离DNA的形式留下一下“指纹”痕迹,而在人类机体中,这些小型的DNA片段就会在血液中被发现;近些年来游离DNA的研究领域应运而生了一种称之为“液体活检”的新技术,该技术可以诊断并且监测某些癌症,鉴别出胎儿机体异常,并且评估移植器官的健康性,进行这些操作仅需要简单的抽血就可以完成,尽管这些检测潜力巨大,但目前其所检测的范围却非常有限。 发表在C

J Mol Med:新型血液检测手段提前诊断1型糖尿病

近日,发表于国际杂志Journal of Molecular Medicine上的一项研究报告中,来自伦敦帝国理工学院的研究人员通过研究,首次在患早期1型糖尿病患者的机体血液中发现了一种循环的特殊小分子,同时研究者还开发出了一种新型的简单血液检测手段,该技术可以在患者症状并未发生之前就可以对患者机体中的生物标志物进行检测。 研究者Mathieu Latreille说道,如果我们可以鉴别并且早日治

Sci Transl Med:通过血液检测肿瘤基因,可预测肿瘤复发

现代医学面临的挑战之一就是如何得知癌症患者机体的肿瘤何时会复发。一项新的研究显示,可通过“跟踪突变”的血液检测可以发现肿瘤患者体内的复发迹象。ICR和皇家马斯登医院进行的这项研究为改变临床肿瘤监测方式和治疗决策具有十分重要的意义。判断肿瘤是否复发主要是依据血液中是否可以检测到肿瘤基因。它将会产生新的肿瘤细胞并导致机体肿瘤的复发。研究对象为55位乳腺癌早期术后的患者。通过对手术后的肿瘤患者进行血液监